A new residential development in North Cambridge is offering science and technology businesses a ready-made solution to one of the city’s most pressing challenges: housing professional staff within easy reach of major employment hubs.
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.
Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.
Coulter Partners successfully completed a search assignment for Melt&Marble and is pleased to announce the placement of Tue Hodal as its first Chief Technology Officer (CTO).
Strategic partnership between Medicines Discovery Catapult and the Crick ensures continued national delivery of KQ Labs, a leading accelerator programme for early-stage innovators.
Brainomix presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.
Ikarovec has highlighted the therapeutic potential of its approach in geographic atrophy and wet AMD, with presentations at major ophthalmic and gene therapy conferences.
Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.
Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.
Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus has been granted a Manufacturer’s/Importer’s Authorisation (MIA) by the MHRA.
New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosis.
AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open in the UK.
Vellos has announced a new partnership with Fifty Years. The partnership will support and inspire the next generation of entrepreneurs across the UK’s deep tech and life sciences sectors.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Dr. Stuart Hughes as Chief Executive Officer at Nuage Therapeutics S.L. (“Nuage”).
eXmoor Pharma has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub.
